Filter
170
Text search:
Bedaquiline
Featured
Recommendations
28
New Publications
51
Language
Document type
No document type
110
Studies & Reports
21
Guidelines
19
Manuals
8
Fact sheets
5
Strategic & Response Plan
3
Situation Updates
2
Training Material
1
Infographics
1
Countries / Regions
Western and Central Europe
16
Eastern Europe
14
India
12
Global
4
Uganda
3
South Africa
3
Latin America and the Carribbean
3
Asia
3
Ethiopia
2
Germany
2
Zambia
2
Namibia
2
South–East Asia Region
2
Eastern Europe and Central Asia
2
Russia
2
Nigeria
1
Philippines
1
Nepal
1
Kenya
1
Bangladesh
1
Malawi
1
Ukraine
1
Botswana
1
Paraguay
1
Estonia
1
Romania
1
Georgia
1
Authors & Publishers
Publication Years
Category
Countries
39
Clinical Guidelines
32
Public Health
3
Pharmacy & Technologies
2
Key Resources
1
Toolboxes
TB
120
HIV
5
AMR
4
NTDs
4
Polio
3
Pharmacy
3
Caregiver
2
Health Financing Toolbox
2
Global Health Education
1
COVID-19
1
Interim policy guidance
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
MMWR: Recommendations and Reports / Vol. 62 / No. 9
Morbidity and Mortality Weekly Report
October 25, 2013
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have be
...
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of
...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis
...
